Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy

摘要

Purpose: Nafamostat mesilate (NM) can be used as a regional anticoagulant for continuous renal replacement therapy (CRRT). The primary aim of this study was to assess the association of the use of NM with risk of bleeding complications and compare it with the use of unfractionated heparin (UFH).